Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(14%)
Results Posted
0%(0 trials)
Terminated
1(14%)

Phase Distribution

Ph not_applicable
4
57%
Ph phase_2
1
14%
Ph phase_1
2
29%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
1(14.3%)
N/ANon-phased studies
4(57.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
Not yet recruiting1
Terminated1
Active, not recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (28.6%)
Phase 21 (14.3%)
N/A4 (57.1%)

Trials by Status

not_yet_recruiting114%
terminated114%
active_not_recruiting114%
unknown114%
completed343%

Recent Activity

1 active trials
Showing 5 of 7
not_yet_recruitingphase_2

RESvEraTrol in Parkinson's Disease (RESET)

NCT07592767
active_not_recruitingnot_applicable

Short Interval Resveratrol Trial in Cardiovascular Surgery

NCT03762096
completedphase_1

Metabolism of Bioactive Dietary Polyphenol Preparation (BDPP)

NCT04421079
terminatednot_applicable

Resveratrol for Exudative Age-Related Macular Degeneration

NCT02625376
completedphase_1

Effects of Trans-Resveratrol in Endothelial Function in Hypertensive Patients

NCT02616822
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07592767Phase 2

RESvEraTrol in Parkinson's Disease (RESET)

Not Yet Recruiting
NCT03762096Not Applicable

Short Interval Resveratrol Trial in Cardiovascular Surgery

Active Not Recruiting
NCT04421079Phase 1

Metabolism of Bioactive Dietary Polyphenol Preparation (BDPP)

Completed
NCT02625376Not Applicable

Resveratrol for Exudative Age-Related Macular Degeneration

Terminated
NCT02616822Phase 1

Effects of Trans-Resveratrol in Endothelial Function in Hypertensive Patients

Completed
NCT02321176Not Applicable

Pharmacokinetics of Trans-resveratrol Based Nutritional Supplement and Its Three Metabolites in Human Eyes and Blood

Unknown
NCT01794351Not Applicable

Cognitive Effects of 500mg Trans-resveratrol

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7